A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06842498)
A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Who can join: Review the eligibility criteria below.
Location: Western Regional Medical Center - City of Hope Phoenix Goodyear — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Western Regional Medical Center - City of Hope Phoenix Goodyear — Goodyear, Arizona
- HonorHealth Research Institute — Scottsdale, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
- VA Greater Los Angeles Healthcare System — Los Angeles, California
- UCLA Clark Urology Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
- New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
- Bioresearch Partner - Aventura — Aventura, Florida
- Bioresearch Partner - Hialeah — Hialeah, Florida
- Biogenix Molecular, LLC — Miami, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- East Jefferson General Hospital Metairie — New Orleans, Louisiana
- New Mexico Oncology Hematology Consultants, Ltd. — Albuquerque, New Mexico
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Henry-Joyce Cancer Clinic — Nashville, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- Oncology Consultants — Houston, Texas
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
- University of Washington Medical Center — Seattle, Washington
- Northwest Medical Specialties, PLLC - Tacoma — Tacoma, Washington
📞 Contact the Study Coordinator
Phone: (415) 978-1466
Email: jmoreno@kyntrabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-Resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-Resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.